

Type of PKD1 Mutation Influences Renal Outcome in ADPKD

Journal of the American Society of Nephrology: JASN
24, 1006-1013

DOI: [10.1681/asn.2012070650](https://doi.org/10.1681/asn.2012070650)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Novel PKD1 and PKD2 mutations in Taiwanese patients with autosomal dominant polycystic kidney disease. Journal of Human Genetics, 2013, 58, 720-727.	2.3	19
3	Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry. BMC Nephrology, 2013, 14, 186.	1.8	33
4	Molecular analysis of a consanguineous Iranian polycystic kidney disease family identifies a PKD2 mutation that aids diagnostics. BMC Nephrology, 2013, 14, 190.	1.8	1
5	The Mutation, a Key Determinant of Phenotype in ADPKD. Journal of the American Society of Nephrology: JASN, 2013, 24, 868-870.	6.1	34
6	A Piece of the Puzzle in the Cardiorenal Conundrum. Journal of the American Society of Nephrology: JASN, 2013, 24, 870-872.	6.1	0
8	Clinical Characteristics and Disease Predictors of a Large Chinese Cohort of Patients with Autosomal Dominant Polycystic Kidney Disease. PLoS ONE, 2014, 9, e92232.	2.5	34
9	Autosomal dominant polycystic kidney disease: genetics, epidemiology, and treatment. Advances in Genomics and Genetics, 2014, , 173.	0.8	3
10	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrology Dialysis Transplantation, 2014, 29, iv26-iv32.	0.7	11
11	Traditional and Proteomic Biomarkers of Autosomal Dominant Polycystic Kidney Disease (ADPKD). , 2014, , 1-15.		0
12	Modification of PCR Conditions and Design of Exon-Specific Primers for the Efficient Molecular Diagnosis of PKD1 Mutations. Kidney and Blood Pressure Research, 2014, 39, 536-545.	2.0	5
13	Genetics and Pathogenesis of Autosomal Dominant Polycystic Kidney Disease: 20 Years On. Human Mutation, 2014, 35, 1393-1406.	2.5	74
14	Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study. BMC Nephrology, 2014, 15, 182.	1.8	14
15	Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrology Dialysis Transplantation, 2014, 29, 1910-1918.	0.7	37
17	Identification of novel PKD1 and PKD2 mutations in Korean patients with autosomal dominant polycystic kidney disease. BMC Medical Genetics, 2014, 15, 129.	2.1	15
18	Novel Functional Complexity of Polycystin-1 by GPS Cleavage <i>In Vivo</i> : Role in Polycystic Kidney Disease. Molecular and Cellular Biology, 2014, 34, 3341-3353.	2.3	50
19	A New PKD1 Mutation Discovered in a Chinese Family with Autosomal Polycystic Kidney Disease. Kidney and Blood Pressure Research, 2014, 39, 1-8.	2.0	4
20	Diagnosis of autosomal dominant polycystic kidney disease using efficient <i>PKD1</i> and <i>PKD2</i> targeted next-generation sequencing. Molecular Genetics & Genomic Medicine, 2014, 2, 412-421.	1.2	67
21	Translational research in ADPKD: lessons from animal models. Nature Reviews Nephrology, 2014, 10, 587-601.	9.6	78

#	ARTICLE	IF	CITATIONS
22	Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2014, 29, iv95-iv105.	0.7	56
24	Kidney volume—a crystal ball for ADPKD prognosis?. Nature Reviews Nephrology, 2014, 10, 485-486.	9.6	6
25	Renal transplantation in autosomal dominant polycystic kidney disease. Nature Reviews Nephrology, 2014, 10, 455-465.	9.6	65
26	Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 258-267.	2.5	52
27	Predictors of Autosomal Dominant Polycystic Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2014, 25, 2399-2418.	6.1	133
28	Pharmacological management of polycystic kidney disease. Expert Opinion on Pharmacotherapy, 2014, 15, 1085-1095.	1.8	26
29	Novel mutations of PKD genes in the Czech population with autosomal dominant polycystic kidney disease. BMC Medical Genetics, 2014, 15, 41.	2.1	23
30	Defective metabolism in polycystic kidney disease: potential for therapy and open questions. Nephrology Dialysis Transplantation, 2014, 29, 1480-1486.	0.7	38
31	Polycystin-1: a master regulator of intersecting cystic pathways. Trends in Molecular Medicine, 2014, 20, 251-260.	6.7	109
33	<scp>NOS3</scp> as a potential modifier of <scp>ADPKD</scp> phenotypic variability: Progress towards an answer. Nephrology, 2014, 19, 733-734.	1.6	1
34	Identification of novel PKD1 and PKD2 mutations in a Chinese population with autosomal dominant polycystic kidney disease. Scientific Reports, 2015, 5, 17468.	3.3	19
37	Risk factors for progression in ADPKD. Current Opinion in Nephrology and Hypertension, 2015, 24, 290-294.	2.0	4
38	A comprehensive search for mutations in the <i><scp>PKD1</scp></i> and <i><scp>PKD2</scp></i> in Japanese subjects with autosomal dominant polycystic kidney disease. Clinical Genetics, 2015, 87, 266-272.	2.0	30
39	The zebrafish Kupffer's vesicle as a model system for the molecular mechanisms by which the lack of Polycystin-2 leads to stimulation of CFTR. Biology Open, 2015, 4, 1356-1366.	1.2	24
40	Genetic Testing in the Assessment of Living Related Kidney Donors at Risk of Autosomal Dominant Polycystic Kidney Disease. Transplantation, 2015, 99, 1023-1029.	1.0	18
41	A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with Autosomal Dominant Polycystic Kidney Disease. BMC Nephrology, 2015, 16, 26.	1.8	24
43	Endothelin and Tubulointerstitial Renal Disease. Seminars in Nephrology, 2015, 35, 197-207.	1.6	16
44	Can ultrasound kidney length qualify as an early predictor of progression to renal insufficiency in autosomal dominant polycystic kidney disease?. Kidney International, 2015, 88, 1449.	5.2	0

#	ARTICLE	IF	CITATIONS
45	The Author Replies. <i>Kidney International</i> , 2015, 88, 1448-1449.	5.2	0
46	Autosomal Dominant Polycystic Kidney Disease: A Path Forward. <i>Seminars in Nephrology</i> , 2015, 35, 524-537.	1.6	18
47	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis. <i>Seminars in Nephrology</i> , 2015, 35, 545-549.e2.	1.6	10
48	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management. <i>Seminars in Nephrology</i> , 2015, 35, 582-589.e17.	1.6	9
49	Rare inherited disorders with renal involvementâ€”approach to the patient. <i>Kidney International</i> , 2015, 87, 901-908.	5.2	18
51	Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 746-753.	6.1	126
52	Traditional and Proteomic Biomarkers of Autosomal Dominant Polycystic Kidney Disease (ADPKD). <i>Biomarkers in Disease</i> , 2015, , 919-937.	0.1	0
53	A polycystin-centric view of cyst formation and disease: the polycystins revisited. <i>Kidney International</i> , 2015, 88, 699-710.	5.2	140
55	The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. <i>Nature Reviews Nephrology</i> , 2015, 11, 515-534.	9.6	115
56	Splicing defects caused by exonic mutations in <i>PKD1</i> as a new mechanism of pathogenesis in autosomal dominant polycystic kidney disease. <i>RNA Biology</i> , 2015, 12, 369-374.	3.1	21
57	Aquaporinâ€”1 retards renal cyst development in polycystic kidney disease by inhibition of Wnt signaling. <i>FASEB Journal</i> , 2015, 29, 1551-1563.	0.5	66
58	Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy. <i>American Journal of Kidney Diseases</i> , 2015, 66, 564-576.	1.9	51
59	Autosomal dominant polycystic kidney disease: the changing face of clinical management. <i>Lancet</i> , The, 2015, 385, 1993-2002.	13.7	227
60	Autosomal dominant polycystic kidney disease in children. <i>Current Opinion in Pediatrics</i> , 2015, 27, 193-200.	2.0	29
61	Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. <i>Drugs</i> , 2015, 75, 1797-1806.	10.9	53
62	Identification of Biomarkers for PKD1 Using Urinary Exosomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1661-1670.	6.1	106
63	Novel therapeutic approaches to autosomal dominant polycystic kidney disease. <i>Translational Research</i> , 2015, 165, 488-498.	5.0	26
64	ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. <i>Pediatric Nephrology</i> , 2015, 30, 15-30.	1.7	132

#	ARTICLE	IF	CITATIONS
65	Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 160-172.	6.1	439
66	Polycystic Kidney Disease. , 2015, , 484-500.		1
67	Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans. Kidney International, 2015, 87, 465-472.	5.2	49
68	Polycystic kidney disease: improving the wellbeing of patients and families. Journal of Renal Nursing, 2016, 8, 66-73.	0.1	0
69	Macrophage Migration Inhibitory Factor in Clinical Kidney Disease. Frontiers in Immunology, 2016, 7, 8.	4.8	25
70	Validation of the Autosomal Dominant Polycystic Kidney Disease Molecular Diagnosis by Next Generation Sequencing technology. Giornale De Technique Nefrologiche & Dialitiche, 2016, 28, 228-231.	0.1	0
71	Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrology Dialysis Transplantation, 2017, 32, gfw243.	0.7	25
72	The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China. Kidney Diseases (Basel, Switzerland), 2016, 2, 111-119.	2.5	19
73	Clinical Manifestation and Management of ADPKD in Western Countries. Kidney Diseases (Basel,) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50	2.5	25
74	Contribution of the <i>TTC21B</i> gene to glomerular and cystic kidney diseases. Nephrology Dialysis Transplantation, 2017, 32, gfv453.	0.7	26
75	Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 952-960.	0.7	54
76	Whole-genome sequencing overcomes pseudogene homology to diagnose autosomal dominant polycystic kidney disease. European Journal of Human Genetics, 2016, 24, 1584-1590.	2.8	63
77	Inherited renal cystic diseases. Abdominal Radiology, 2016, 41, 1035-1051.	2.1	10
78	Genetic Mechanisms of ADPKD. Advances in Experimental Medicine and Biology, 2016, 933, 13-22.	1.6	34
80	Attitudes in Patients with Autosomal Dominant Polycystic Kidney Disease Toward Prenatal Diagnosis and Preimplantation Genetic Diagnosis. Genetic Testing and Molecular Biomarkers, 2016, 20, 741-746.	0.7	34
81	Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context. Journal of the American Society of Nephrology: JASN, 2016, 27, 3530-3538.	6.1	34
82	The Patterns, Risk Factors, and Prediction of Progression in Chronic Kidney Disease: A Narrative Review. Seminars in Nephrology, 2016, 36, 273-282.	1.6	38
83	Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrology Dialysis Transplantation, 2017, 32, gfw240.	0.7	139

#	ARTICLE	IF	CITATIONS
84	Identification of MMP1 as a novel risk factor for intracranial aneurysms in ADPKD using iPSC models. Scientific Reports, 2016, 6, 30013.	3.3	34
85	mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Nature Communications, 2016, 7, 10786.	12.8	55
87	Deciphering Variability of PKD1 and PKD2 in an Italian Cohort of 643 Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Scientific Reports, 2016, 6, 30850.	3.3	28
88	Diagnostic Evaluation as a Biomarker in Patients with ADPKD. Advances in Experimental Medicine and Biology, 2016, 933, 85-103.	1.6	4
89	Clinical Trials and a View Toward the Future of ADPKD. Advances in Experimental Medicine and Biology, 2016, 933, 105-121.	1.6	2
90	ADPKD: clinical issues before and after renal transplantation. Journal of Nephrology, 2016, 29, 755-763.	2.0	2
91	Mutations in GANAB , Encoding the Glucosidase II \pm Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. American Journal of Human Genetics, 2016, 98, 1193-1207.	6.2	345
92	Genetic diagnosis of autosomal dominant polycystic kidney disease: linkage analysis versus direct mutation analysis. Kidney Research and Clinical Practice, 2016, 35, 67-68.	2.2	3
93	The Polycystin-1, Lipoxigenase, and II \pm -Toxin Domain Regulates Polycystin-1 Trafficking. Journal of the American Society of Nephrology: JASN, 2016, 27, 1159-1173.	6.1	29
94	Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 1861-1868.	6.1	123
95	Autosomal dominant polycystic kidney disease. BMJ, The, 2016, 352, i679.	6.0	30
96	Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 2872-2884.	6.1	136
97	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2016, 31, 337-348.	0.7	206
98	Three exonic mutations in polycystic kidney disease-2 gene (PKD2) alter splicing of its pre-mRNA in a minigene system. Gene, 2016, 578, 117-123.	2.2	13
99	Slowing Polycystic Kidney Disease by Fasting. Journal of the American Society of Nephrology: JASN, 2016, 27, 1268-1270.	6.1	5
100	Therapeutic targets for polycystic kidney disease. Expert Opinion on Therapeutic Targets, 2016, 20, 35-45.	3.4	5
101	Comprehensive PKD1 and PKD2 Mutation Analysis in Prenatal Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 722-729.	6.1	68
102	The PROPKD Score. Journal of the American Society of Nephrology: JASN, 2016, 27, 942-951.	6.1	245

#	ARTICLE	IF	CITATIONS
103	LRP5 variants may contribute to ADPKD. European Journal of Human Genetics, 2016, 24, 237-242.	2.8	28
104	The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatric Nephrology, 2017, 32, 31-42.	1.7	32
105	Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease. Pediatric Nephrology, 2017, 32, 893-896.	1.7	21
106	Polycystic Kidney Disease without an Apparent Family History. Journal of the American Society of Nephrology: JASN, 2017, 28, 2768-2776.	6.1	75
107	Advances in renal genetic diagnosis. Cell and Tissue Research, 2017, 369, 93-104.	2.9	10
108	Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression. American Journal of Physiology - Renal Physiology, 2017, 312, F577-F588.	2.7	26
109	Ciliary Mechanisms of Cyst Formation in Polycystic Kidney Disease. Cold Spring Harbor Perspectives in Biology, 2017, 9, a028209.	5.5	103
110	Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769335.	1.1	45
111	Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769578.	1.1	28
112	PKD2 -Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis. American Journal of Kidney Diseases, 2017, 70, 476-485.	1.9	50
113	Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans. Journal of Nephrology, 2017, 30, 511-519.	2.0	28
114	Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial. American Journal of Transplantation, 2017, 17, 2640-2649.	4.7	36
115	Diagnostic and Prognostic Biomarkers in Autosomal Dominant Polycystic Kidney Disease. , 2017, , 513-530.		0
116	New treatment paradigms for ADPKD: moving towards precision medicine. Nature Reviews Nephrology, 2017, 13, 750-768.	9.6	60
117	Rare diseases, rare presentations: recognizing atypical inherited kidney disease phenotypes in the age of genomics. CKJ: Clinical Kidney Journal, 2017, 10, 586-593.	2.9	17
118	Genetic diagnosis of polycystic kidney disease, Alport syndrome, and thalassemia minor in a large Chinese family. Clinical Science, 2017, 131, 2427-2438.	4.3	3
119	Genetics and Autosomal Dominant Polycystic Kidney Disease Progression. Contributions To Nephrology, 2017, 190, 117-123.	1.1	2
120	TRPP2 ion channels: Critical regulators of organ morphogenesis in health and disease. Cell Calcium, 2017, 66, 25-32.	2.4	26

#	ARTICLE	IF	CITATIONS
121	Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency. Scientific Reports, 2017, 7, 7161.	3.3	53
124	Recent advances in management of autosomal-dominant polycystic kidney disease. American Journal of Health-System Pharmacy, 2017, 74, 1959-1968.	1.0	2
125	Polycystic Kidney Disease. , 2017, 7, 945-975.		41
126	Methodological issues in clinical trials of polycystic kidney disease: a focused review. Journal of Nephrology, 2017, 30, 363-371.	2.0	7
127	The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Diseaseâ€”A Primer for Clinicians. Frontiers in Pediatrics, 2017, 5, 279.	1.9	33
128	Identification and Expression Analysis of the Complete Family of Zebrafish pkd Genes. Frontiers in Cell and Developmental Biology, 2017, 5, 5.	3.7	23
129	Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients. BMC Nephrology, 2017, 18, 241.	1.8	10
130	Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease. Current Gene Therapy, 2017, 17, 43-49.	2.0	3
131	Isolated polycystic liver disease genes define effectors of polycystin-1 function. Journal of Clinical Investigation, 2017, 127, 1772-1785.	8.2	137
132	Renal injury progression in autosomal dominant polycystic kidney disease: a look beyond the cysts. Nephrology Dialysis Transplantation, 2018, 33, 1887-1895.	0.7	17
133	The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease. International Urology and Nephrology, 2018, 50, 1293-1300.	1.4	2
134	Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan. CKJ: Clinical Kidney Journal, 2018, 11, 62-69.	2.9	25
135	Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney International, 2018, 93, 691-699.	5.2	76
136	Genomic medicine for kidney disease. Nature Reviews Nephrology, 2018, 14, 83-104.	9.6	102
137	Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. American Journal of Kidney Diseases, 2018, 71, 666-676.	1.9	30
138	Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. American Journal of Human Genetics, 2018, 102, 832-844.	6.2	208
139	Identification of Three Novel Frameshift Mutations in the PKD1 Gene in Iranian Families with Autosomal Dominant Polycystic Kidney Disease Using Efficient Targeted Next-Generation Sequencing. Kidney and Blood Pressure Research, 2018, 43, 471-478.	2.0	6
140	Preimplantation Genetic Diagnosis Counseling in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2018, 72, 866-872.	1.9	24

#	ARTICLE	IF	CITATIONS
141	Novel Mutations in the PKD1 and PKD2 Genes of Chinese Patients with Autosomal Dominant Polycystic Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 297-309.	2.0	20
142	Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 645-652.	0.7	31
143	Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 13-23.	6.1	223
144	Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective. <i>Kidney International</i> , 2018, 93, 716-726.	5.2	46
145	Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression. <i>Kidney International Reports</i> , 2018, 3, 291-301.	0.8	26
146	Clinical management of polycystic liver disease. <i>Journal of Hepatology</i> , 2018, 68, 827-837.	3.7	112
147	ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. <i>American Journal of Kidney Diseases</i> , 2018, 71, 294-296.	1.9	5
148	Quercetin inhibits renal cyst growth <i>in vitro</i> and <i>via</i> parenteral injection in a polycystic kidney disease mouse model. <i>Food and Function</i> , 2018, 9, 389-396.	4.6	17
149	Erbliche Zystennierenerkrankungen: Autosomal-dominante und autosomal-rezessive polyzystische Nierenerkrankung (ADPKD und ARPKD). <i>Medizinische Genetik</i> , 2018, 30, 422-428.	0.2	0
150	A novel frameshift PKD1 mutation in a Chinese patient with autosomal dominant polycystic kidney disease and azoospermia: A case report. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 507-511.	1.8	0
151	Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2018, 5, 205435811880158.	1.1	27
152	Renal Cystic Disease in the Elderly. , 2018, , 148-148.		0
153	Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, i14-i26.	2.9	16
154	Polycystic kidney disease. <i>Nature Reviews Disease Primers</i> , 2018, 4, 50.	30.5	435
156	Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression. <i>American Journal of Nephrology</i> , 2018, 48, 308-317.	3.1	15
157	Novel mutations of PKD genes in Chinese patients suffering from autosomal dominant polycystic kidney disease and seeking assisted reproduction. <i>BMC Medical Genetics</i> , 2018, 19, 186.	2.1	9
158	A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2458-2470.	6.1	163
159	Early cardiovascular manifestations in children and adolescents with autosomal dominant polycystic kidney disease: a single center study. <i>Pediatric Nephrology</i> , 2018, 33, 1513-1521.	1.7	15

#	ARTICLE	IF	CITATIONS
160	A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases. <i>Kidney International</i> , 2018, 94, 363-371.	5.2	109
162	Antenatally Diagnosed ADPKD. <i>Kidney International Reports</i> , 2018, 3, 1214-1217.	0.8	4
163	Bilineal inheritance of pathogenic PKD1 and PKD2 variants in a Czech family with autosomal dominant polycystic kidney disease – a case report. <i>BMC Nephrology</i> , 2018, 19, 163.	1.8	9
164	Is It Ethical to Test Apparently “Healthy” Children for Autosomal Dominant Polycystic Kidney Disease and Risk Medicalizing Thousands?. <i>Frontiers in Pediatrics</i> , 2017, 5, 291.	1.9	6
165	A Review of the Imaging Techniques for Measuring Kidney and Cyst Volume in Establishing Autosomal Dominant Polycystic Kidney Disease Progression. <i>American Journal of Nephrology</i> , 2018, 48, 67-78.	3.1	51
166	Genetics of Autosomal Recessive Polycystic Kidney Disease and Its Differential Diagnoses. <i>Frontiers in Pediatrics</i> , 2017, 5, 221.	1.9	92
167	A potentially crucial role of the PKD1 C-terminal tail in renal prognosis. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 395-404.	1.6	6
168	Metabolism and mitochondria in polycystic kidney disease research and therapy. <i>Nature Reviews Nephrology</i> , 2018, 14, 678-687.	9.6	122
169	Classical Polycystic Kidney Disease: Gene Structures and Mutations and Protein Structures and Functions. , 2018, , 3-26.		1
170	The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. <i>PLoS ONE</i> , 2018, 13, e0190430.	2.5	57
171	Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2319-2328.	3.6	23
172	Baseline characteristics of the autosomal dominant polycystic kidney disease sub-cohort of the Korean N cohort study for outcomes in patients with chronic kidney disease. <i>Nephrology</i> , 2019, 24, 422-429.	1.6	13
173	Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 100-111.	1.6	9
174	Prognostic Performance of Kidney Volume Measurement for Polycystic Kidney Disease: A Comparative Study of Ellipsoid vs. Manual Segmentation. <i>Scientific Reports</i> , 2019, 9, 10996.	3.3	11
175	Bilateral Nephrectomy for Adult Polycystic Kidney Disease Does Not Affect the Graft Function of Transplant Patients and Does Not Result in Sensitisation. <i>BioMed Research International</i> , 2019, 2019, 1-6.	1.9	9
176	Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 823-833.	4.5	25
177	Co-segregation of candidate polymorphism rs201204878 of the PKD1 gene in a large Iranian family with autosomal dominant polycystic disease. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 1345-1349.	1.8	0
178	Kidney and cystic volume imaging for disease presentation and progression in the cat autosomal dominant polycystic kidney disease large animal model. <i>BMC Nephrology</i> , 2019, 20, 259.	1.8	8

#	ARTICLE	IF	CITATIONS
179	Clinical characteristics of individual organ system disease in non-motile ciliopathies. Translational Science of Rare Diseases, 2019, 4, 1-23.	1.5	14
180	Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors. American Journal of Nephrology, 2019, 50, 375-385.	3.1	24
181	<p>Autosomal dominant polycystic kidney disease: updated perspectives</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1041-1052.	2.0	21
182	Exome sequencing of Saudi Arabian patients with ADPKD. Renal Failure, 2019, 41, 842-849.	2.1	6
183	Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine, 2019, 47, 436-445.	6.1	50
184	Genetic, clinical and biochemical characterization of a large cohort of patients with hyaline fibromatosis syndrome. Orphanet Journal of Rare Diseases, 2019, 14, 209.	2.7	7
185	ADPedKD: A Global Online Platform on the Management of Children With ADPKD. Kidney International Reports, 2019, 4, 1271-1284.	0.8	20
186	TRPP2 dysfunction decreases ATP-evoked calcium, induces cell aggregation and stimulates proliferation in T lymphocytes. BMC Nephrology, 2019, 20, 355.	1.8	12
187	Spleen phenotype in autosomal dominant polycystic kidney disease. Clinical Radiology, 2019, 74, 975.e17-975.e24.	1.1	9
188	Molecular Structure of the PKD Protein ComplexÂFinally Solved. American Journal of Kidney Diseases, 2019, 73, 620-623.	1.9	2
189	Interleukin-1 receptor activation aggravates autosomal dominant polycystic kidney disease by modulating regulated necrosis. American Journal of Physiology - Renal Physiology, 2019, 317, F221-F228.	2.7	17
190	Multiple urinary tract infections are associated with genotype and phenotype in adult polycystic kidney disease. Clinical and Experimental Nephrology, 2019, 23, 1188-1195.	1.6	5
191	Histone Deacetylase Inhibitors Reduce Cysts by Activating Autophagy in Polycystic Kidney Disease. Kidney Diseases (Basel, Switzerland), 2019, 5, 163-172.	2.5	8
192	Biallelic PKD1 mutations underlie early-onset autosomal dominant polycystic kidney disease in Saudi Arabian families. Pediatric Nephrology, 2019, 34, 1615-1623.	1.7	21
193	Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease. International Urology and Nephrology, 2019, 51, 1191-1197.	1.4	6
194	Mutation analyses by next-generation sequencing and multiplex ligation-dependent probe amplification in Japanese autosomal dominant polycystic kidney disease patients. Clinical and Experimental Nephrology, 2019, 23, 1022-1030.	1.6	16
195	Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney International, 2019, 95, 1253-1261.	5.2	59
196	Identification of a pathogenic mutation in a Chinese pedigree with polycystic kidney disease. Molecular Medicine Reports, 2019, 19, 2671-2679.	2.4	4

#	ARTICLE	IF	CITATIONS
197	Genotype-Clinical Correlations in Polycystic Kidney Disease with No Apparent Family History. American Journal of Nephrology, 2019, 49, 233-240.	3.1	5
198	GANAB and PKD1 Variations in a 12 Years Old Female Patient With Early Onset of Autosomal Dominant Polycystic Kidney Disease. Frontiers in Genetics, 2019, 10, 44.	2.3	11
199	Autosomal dominant polycystic kidney disease. Lancet, The, 2019, 393, 919-935.	13.7	337
200	Aquaporinâ€³ deficiency slows cyst enlargement in experimental mouse models of autosomal dominant polycystic kidney disease. FASEB Journal, 2019, 33, 6185-6196.	0.5	14
201	Generation of primary cells from ADPKD and normal human kidneys. Methods in Cell Biology, 2019, 153, 1-23.	1.1	6
202	New Ways of Finding New Genes for Old Diseases. Journal of the American Society of Nephrology: JASN, 2019, 30, 2037-2039.	6.1	0
203	Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models. Journal of the American Society of Nephrology: JASN, 2019, 30, 2113-2127.	6.1	39
204	Genetic Characteristics of Korean Patients with Autosomal Dominant Polycystic Kidney Disease by Targeted Exome Sequencing. Scientific Reports, 2019, 9, 16952.	3.3	7
205	Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 1453-1460.	0.7	33
206	Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models. Pediatric Nephrology, 2019, 34, 1697-1715.	1.7	4
207	Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). American Journal of Kidney Diseases, 2019, 73, 533-541.	1.9	16
208	Early and Severe Polycystic Kidney Disease and Related Ciliopathies: An Emerging Field of Interest. Nephron, 2019, 141, 50-60.	1.8	43
209	Population data improves variant interpretation in autosomal dominant polycystic kidney disease. Genetics in Medicine, 2019, 21, 1425-1434.	2.4	11
210	Relationship of Seminal Megavesicles, Prostate Median Cysts, and Genotype in Autosomal Dominant Polycystic Kidney Disease. Journal of Magnetic Resonance Imaging, 2019, 49, 894-903.	3.4	9
211	Identification of novel mutations and risk assessment of Han Chinese patients with autosomal dominant polycystic kidney disease. Nephrology, 2019, 24, 504-510.	1.6	3
212	Polycystic Kidney Disease. , 2020, , 771-797.		1
213	Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 370-382.	5.2	44
214	Divergent function of polycystin 1 and polycystin 2 in cell size regulation. Biochemical and Biophysical Research Communications, 2020, 521, 290-295.	2.1	12

#	ARTICLE	IF	CITATIONS
215	Polycystic Kidney Disease Caused by Bilineal Inheritance of Truncating PKD1 as Well as PKD2 Mutations. <i>Kidney International Reports</i> , 2020, 5, 1828-1832.	0.8	0
216	Clinical Genetic Screening in Adult Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1497-1510.	4.5	53
217	Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan. <i>American Journal of Nephrology</i> , 2020, 51, 881-890.	3.1	5
218	The Controversial Role of Fibrosis in Autosomal Dominant Polycystic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8936.	4.1	13
219	Transient receptor potential channels: current perspectives on evolution, structure, function and nomenclature. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2020, 287, 20201309.	2.6	54
220	Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients. <i>Nephron</i> , 2020, 144, 525-536.	1.8	1
221	Metabolic Changes in Polycystic Kidney Disease as a Potential Target for Systemic Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6093.	4.1	12
222	Rare genetic causes of complex kidney and urological diseases. <i>Nature Reviews Nephrology</i> , 2020, 16, 641-656.	9.6	27
223	Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Nephrology</i> , 2020, 51, 745-751.	3.1	5
225	Matching clinical and genetic diagnoses in autosomal dominant polycystic kidney disease reveals novel phenocopies and potential candidate genes. <i>Genetics in Medicine</i> , 2020, 22, 1374-1383.	2.4	30
226	Detection of a novel mutation in a Tunisian child with polycystic kidney disease. <i>IUBMB Life</i> , 2020, 72, 1799-1806.	3.4	1
227	Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. <i>Kidney360</i> , 2020, 1, 648-656.	2.1	4
228	Gene Panel Analysis in a Large Cohort of Patients With Autosomal Dominant Polycystic Kidney Disease Allows the Identification of 80 Potentially Causative Novel Variants and the Characterization of a Complex Genetic Architecture in a Subset of Families. <i>Frontiers in Genetics</i> , 2020, 11, 464.	2.3	26
229	<p>Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges</p>. <i>International Journal of Women's Health</i> , 2020, Volume 12, 409-422.	2.6	9
230	Coexistence of autosomal dominant polycystic kidney disease type 1 and hereditary renal hypouricemia type 2: A model of early‑onset and fast cyst progression. <i>Clinical Genetics</i> , 2020, 97, 857-868.	2.0	3
231	Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease. <i>Cellular Signalling</i> , 2020, 73, 109704.	3.6	19
232	Prediction of Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease Using PKD1/PKD2 Mutations. <i>Journal of Clinical Medicine</i> , 2020, 9, 146.	2.4	18
233	Ganoderic acid A is the effective ingredient of Ganoderma triterpenes in retarding renal cyst development in polycystic kidney disease. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 782-790.	6.1	20

#	ARTICLE	IF	CITATIONS
234	A high throughput zebrafish chemical screen reveals ALK5 and non-canonical androgen signalling as modulators of the <i>pkd2^{Δ~}/Δ~</i> phenotype. Scientific Reports, 2020, 10, 72.	3.3	18
235	Adhesion GPCRs as a paradigm for understanding polycystin-1 ^{ΔG} protein regulation. Cellular Signalling, 2020, 72, 109637.	3.6	16
236	Extracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease. Cellular Signalling, 2020, 72, 109646.	3.6	38
237	Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review. Kidney Medicine, 2020, 2, 196-208.	2.0	23
238	Autosomal dominant polycystic kidney disease in absence of renal cyst formation illustrates genetic interaction between WT1 and PKD1. Journal of Medical Genetics, 2021, 58, 140-144.	3.2	2
239	Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease. Genetics in Medicine, 2021, 23, 689-697.	2.4	31
240	A novel monogenic preimplantation genetic testing strategy for sporadic polycystic kidney caused by <i><i>de novo</i><scp><i>PKD1</i></scp></i> mutation. Clinical Genetics, 2021, 99, 250-258.	2.0	11
241	Targeted broad-based genetic testing by next-generation sequencing informs diagnosis and facilitates management in patients with kidney diseases. Nephrology Dialysis Transplantation, 2021, 36, 295-305.	0.7	34
242	A case of <i><i>TSC2ΔPKD1</i></i> contiguous deletion syndrome: Clinical features and effective treatment for epilepsy. International Journal of Developmental Neuroscience, 2021, 81, 191-199.	1.6	4
243	Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?. Kidney Diseases (Basel, Switzerland), 2021, 7, 343-349.	2.5	3
244	Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 204-212.	4.5	17
245	Urinary exosome proteomic profiling defines stage-specific rapid progression of autosomal dominant polycystic kidney disease and tolvaptan efficacy. BBA Advances, 2021, 1, 100013.	1.6	4
246	The genetic landscape of polycystic kidney disease in Ireland. European Journal of Human Genetics, 2021, 29, 827-838.	2.8	11
247	Evolutionary demographic models reveal the strength of purifying selection on susceptibility alleles to late-onset diseases. Nature Ecology and Evolution, 2021, 5, 392-400.	7.8	11
248	Biallelic Mutations in <i><i>DNAB11</i></i> are Associated with Prenatal Polycystic Kidney Disease in a Turkish Family. Molecular Syndromology, 2021, 12, 179-185.	0.8	3
249	Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 374-383.	4.5	15
250	Characteristics of Patients with End-Stage Kidney Disease in ADPKD. Kidney International Reports, 2021, 6, 755-767.	0.8	10
251	Polycystic liver disease genes: Practical considerations for genetic testing. European Journal of Medical Genetics, 2021, 64, 104160.	1.3	15

#	ARTICLE	IF	CITATIONS
252	Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2021, 6, 953-961.	0.8	9
253	Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2021, 6, 1687-1698.	0.8	12
254	Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease. <i>Hepatology International</i> , 2021, 15, 791-803.	4.2	12
255	Nephroplex: a kidney-focused NGS panel highlights the challenges of PKD1 sequencing and identifies a founder BBS4 mutation. <i>Journal of Nephrology</i> , 2021, 34, 1855-1874.	2.0	6
256	Role of the polycystins as mechanosensors of extracellular stiffness. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F693-F705.	2.7	14
257	Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States. <i>Current Medical Research and Opinion</i> , 2021, 37, 1155-1162.	1.9	3
258	Polycystin-1 Enhances Stemness Potential of Umbilical Cord Blood-Derived Mesenchymal Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4868.	4.1	3
259	Increased risk of pulmonary and extrapulmonary tuberculosis infection in patients with polycystic kidney disease: a nationwide population-based study with propensity score-matching analysis. <i>Journal of Translational Medicine</i> , 2021, 19, 253.	4.4	1
260	Mechanism and application of metformin in kidney diseases: An update. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111454.	5.6	44
262	The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2021, 99, 1392-1407.	5.2	32
263	Systematic Review of Genotype-Phenotype Correlations in Frasier Syndrome. <i>Kidney International Reports</i> , 2021, 6, 2585-2593.	0.8	12
264	Identification of novel single-nucleotide variants altering RNA splicing of PKD1 and PKD2. <i>Journal of Human Genetics</i> , 2021, , .	2.3	0
265	<scp><i>PKD2</i></scp> gene variants in Chinese patients with autosomal dominant polycystic kidney disease. <i>Clinical Genetics</i> , 2021, 100, 340-347.	2.0	1
266	Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patients. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 767-779.	1.7	8
267	The causes and consequences of paediatric kidney disease on adult nephrology care. <i>Pediatric Nephrology</i> , 2022, 37, 1245-1261.	1.7	8
268	MiR-4787-5p Regulates Vascular Smooth Muscle Cell Apoptosis by Targeting PKD1 and Inhibiting the PI3K/Akt/FKHR Pathway. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 288-296.	1.9	4
269	Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy. <i>American Journal of Kidney Diseases</i> , 2021, 78, 282-292.	1.9	45
270	Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. <i>American Journal of Kidney Diseases</i> , 2022, 79, 518-526.	1.9	26

#	ARTICLE	IF	CITATIONS
271	PKD1-Associated Arachnoid Cysts in Autosomal Dominant Polycystic Kidney Disease. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105943.	1.6	5
272	A Presumed Synonymous Mutation of PKD2 Caused Autosomal Dominant Polycystic Kidney Disease in a Chinese Family. Current Medical Science, 2021, 41, 1029-1036.	1.8	3
273	Clinical and Genetic Features of Autosomal Dominant Alport Syndrome: A Cohort Study. American Journal of Kidney Diseases, 2021, 78, 560-570.e1.	1.9	48
274	Kidney Diseases. , 2021, , 553-582.		1
275	Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing. European Journal of Human Genetics, 2021, 29, 760-770.	2.8	20
276	Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease. Pediatric Nephrology, 2021, 36, 2639-2658.	1.7	10
278	The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight, 2020, 5, .	5.0	41
279	Altered trafficking and stability of polycystins underlie polycystic kidney disease. Journal of Clinical Investigation, 2014, 124, 5129-5144.	8.2	125
280	Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. Journal of Clinical Investigation, 2014, 124, 2315-2324.	8.2	261
281	Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. Journal of Clinical Investigation, 2015, 125, 607-620.	8.2	107
282	Clinical Features of 167 Inpatients with Autosomal Dominant Polycystic Kidney Disease at a Single Center in China. Medical Science Monitor, 2018, 24, 6498-6505.	1.1	5
283	Screening for Unruptured Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Survey of 420 Nephrologists. PLoS ONE, 2016, 11, e0153176.	2.5	17
284	Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria. PLoS ONE, 2016, 11, e0161376.	2.5	11
285	Role of Inflammation in Polycystic Kidney Disease. , 0, , 335-373.		19
286	Clinical Trials in Autosomal Dominant Polycystic Kidney Disease. , 0, , 109-135.		6
287	Intracranial Aneurysms In Autosomal Dominant Polycystic Kidney Disease: A Nephrologist's Perspective. Journal of Nephrology Research, 2015, 1, 15-18.	1.0	2
288	Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease. Current Medicinal Chemistry, 2019, 26, 3081-3102.	2.4	4
289	Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Korean Journal of Medicine, 2015, 89, 169-178.	0.3	3

#	ARTICLE	IF	CITATIONS
291	Renal plasticity revealed through reversal of polycystic kidney disease in mice. <i>Nature Genetics</i> , 2021, 53, 1649-1663.	21.4	57
293	Molecular Basis, Diagnostic Challenges and Therapeutic Approaches of Bartter and Gitelman Syndromes: A Primer for Clinicians. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11414.	4.1	19
295	Polycystic Kidney Disease: ADPKD and ARPKD. , 2016, , 333-367.		2
296	Intracranial Manifestations of Autosomal Dominant Polycystic Kidney Disease. <i>International Journal of Neurology Research</i> , 2016, 2, 210-215.	0.2	0
297	Polycystic Kidney Disease. , 2016, , 277-290.		1
298	Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease. , 2018, , 133-142.		0
299	The Polycystins and Polycystic Kidney Disease. <i>Physiology in Health and Disease</i> , 2020, , 1149-1186.	0.3	0
300	Mutational analysis of PKD1 gene in a Chinese family with autosomal dominant polycystic kidney disease. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13289-92.	0.5	2
301	The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1. <i>Journal of Nephro pharmacology</i> , 2016, 5, 24-25.	0.4	1
302	Analysis of mutations in six Chinese families with autosomal dominant polycystic kidney disease. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 8123-8136.	0.0	0
303	Mainstreaming Genetic Testing for Adult Patients With Autosomal Dominant Polycystic Kidney Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110550.	1.1	8
304	Autosomal Dominant Polycystic Kidney Disease “ Genetics and Cyst Formation. <i>International Journal of Clinical Pathology and Diagnosis</i> , 2018, 2, .	0.0	0
306	Increased Body Fat and Organic Acid Anions Production Are Associated with Larger Kidney Size in ADPKD. <i>Medicina (Lithuania)</i> , 2022, 58, 152.	2.0	0
307	Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, F258-F267.	2.7	17
308	The utility of a genetic kidney disease clinic employing a broad range of genomic testing platforms: experience of the Irish Kidney Gene Project. <i>Journal of Nephrology</i> , 2022, 35, 1655-1665.	2.0	14
309	Diagnosis and risk factors for intracranial aneurysms in autosomal polycystic kidney disease: a cross-sectional study from the Genkyst cohort. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2223-2233.	0.7	6
310	Autosomal dominant polycystic kidney disease (ADPKD) in Tunisia: From molecular genetics to the development of prognostic tools. <i>Gene</i> , 2022, 817, 146174.	2.2	0
311	Emerging Role of Clinical Genetics in CKD. <i>Kidney Medicine</i> , 2022, 4, 100435.	2.0	12

#	ARTICLE	IF	CITATIONS
314	Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD. <i>Kidney International Reports</i> , 2022, 7, 1037-1048.	0.8	6
315	Rapidly Progressing to ESRD in an Individual with Coexisting ADPKD and Masked Klinefelter and Citelman Syndromes. <i>Genes</i> , 2022, 13, 394.	2.4	1
316	Germline Mutations for Kidney Volume in ADPKD. <i>Kidney International Reports</i> , 2022, 7, 537-546.	0.8	6
317	Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options. <i>Kidney Research and Clinical Practice</i> , 2022, 41, 422-431.	2.2	11
318	Polycystic Kidney/Liver Disease. <i>Clinics in Liver Disease</i> , 2022, 26, 229-243.	2.1	5
319	Metformin induces lactate accumulation and accelerates renal cyst progression in <i>Pkd1</i> -deficient mice. <i>Human Molecular Genetics</i> , 2022, 31, 1560-1573.	2.9	11
320	Factors that lead to dialysis as the preferred treatment modality for patients with chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 180-184.	2.0	0
324	Research Progress of Autosomal Dominant Polycystic Kidney Disease. <i>Advances in Clinical Medicine</i> , 2022, 12, 3337-3343.	0.0	0
325	Changing the Outcome of a Pediatric Disease: Part I – Clinical Features of ADPKD. <i>Current Treatment Options in Pediatrics</i> , 2022, 8, 65-76.	0.6	2
326	Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 585-604.	17.8	15
327	Establishment and Characterization of MUi027-A: A Novel Patient-Derived Cell Line of Polycystic Kidney Disease with PKD1 Mutation. <i>Journal of Personalized Medicine</i> , 2022, 12, 766.	2.5	2
328	Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients. <i>American Journal of Nephrology</i> , 2022, 53, 470-480.	3.1	3
330	Identification of osteopontin as a urinary biomarker for autosomal dominant polycystic kidney disease progression. <i>Kidney Research and Clinical Practice</i> , 2022, 41, 730-740.	2.2	6
331	Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study. <i>CJ: Clinical Kidney Journal</i> , 2022, 15, 2063-2071.	2.9	3
332	Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 976-985.	4.5	6
333	PKD2 founder mutation is the most common mutation of polycystic kidney disease in Taiwan. <i>Npj Genomic Medicine</i> , 2022, 7, .	3.8	4
334	PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression. <i>Nature Communications</i> , 2022, 13, .	12.8	17
335	Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	0

#	ARTICLE	IF	CITATIONS
336	Cystic Diseases of the Kidney. , 2023, , 39-94.		1
337	A single-center analysis of genotypeâ€“phenotype characteristics of Chinese patients with autosomal dominant polycystic kidney disease by targeted exome sequencing. Frontiers in Genetics, 0, 13, .	2.3	1
338	Autosomal Dominant Polycystic Kidney Disease. , 2022, , 1171-1196.		0
339	Genetic Testing for the Management of Kidney Disease. , 2022, , 1-15.		0
340	XBP1 Activation Reduces Severity of Polycystic Kidney Disease due to a Nontruncating Polycystin-1 Mutation in Mice. Journal of the American Society of Nephrology: JASN, 2023, 34, 110-121.	6.1	3
342	Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. Scientific Reports, 2022, 12, .	3.3	4
343	The genetic landscape of autosomal dominant polycystic kidney disease in Kuwait. CKJ: Clinical Kidney Journal, 2023, 16, 355-366.	2.9	6
344	Identification and Characterization of Novel Mutations in Chronic Kidney Disease (CKD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Saudi Subjects by Whole-Exome Sequencing. Medicina (Lithuania), 2022, 58, 1657.	2.0	3
345	Identification of Serum Metabolites for Predicting Chronic Kidney Disease Progression according to Chronic Kidney Disease Cause. Metabolites, 2022, 12, 1125.	2.9	4
346	Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD). Journal of Clinical Medicine, 2022, 11, 6528.	2.4	5
347	Consensus document on autosomal dominant polycystic kindey disease from the Spanish Working Group on Inherited Kindey Diseases. Review 2020. Nefrologia, 2022, 42, 367-389.	0.4	1
348	Autosomal Dominant Polycystic Kidney Disease: Role of Imaging in Diagnosis and Management. Radiographics, 2023, 43, .	3.3	3
349	Practical Issues in the Management of Polycystic Kidney Disease: Blood Pressure and Water Balance. Electrolyte and Blood Pressure, 2022, 20, 10.	1.8	1
350	Health Disparities in Kidney Failure Among Patients With Autosomal Dominant Polycystic Kidney Disease: A Cross-Sectional Study. Kidney Medicine, 2023, 5, 100577.	2.0	1
351	Severe parental phenotype associates with hypertension in children with ADPKD. Pediatric Nephrology, 0, , .	1.7	0
352	Review of the Use of Animal Models of Human Polycystic Kidney Disease for the Evaluation of Experimental Therapeutic Modalities. Journal of Clinical Medicine, 2023, 12, 668.	2.4	4
353	A Low-Cost Sequencing Platform for Rapid Genotyping in ADPKD and its Impact on Clinical Care. Kidney International Reports, 2022, , .	0.8	0
354	The Clinical and Mutational Spectrum of 69 Turkish Children with Autosomal Recessive or Autosomal Dominant Polycystic Kidney Disease: A Multicenter Retrospective Cohort Study. Nephron, 0, , 1-14.	1.8	2

#	ARTICLE	IF	CITATIONS
355	Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	1
356	Renal Transplantation in Autosomal Dominant Polycystic Kidney Disease. , 0, , 56-62.		1
357	Autosomal Dominant Polycystic Kidney Disease: What Do We Need To Know For Counselling?. , 0, , 51-60.		1
359	Blocker displacement amplification-based genetic diagnosis for autosomal dominant polycystic kidney disease and the clinical outcomes of preimplantation genetic testing. <i>Journal of Assisted Reproduction and Genetics</i> , 2023, 40, 783-792.	2.5	1
360	OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD. <i>Kidney International Reports</i> , 2023, 8, 989-1001.	0.8	7
361	Cystic diseases of the kidneys: From bench to bedside. <i>Indian Journal of Nephrology</i> , 2023, .	0.5	0
362	Association of polygenic scores with chronic kidney disease phenotypes in a longitudinal study of older adults. <i>Kidney International</i> , 2023, 103, 1156-1166.	5.2	3
363	Polycystic Kidney Disease: ADPKD and ARPKD. , 2023, , 317-348.		0
364	Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease. <i>Physiological Reports</i> , 2023, 11, .	1.7	1
365	Molecular genetic diagnosis of kidney ciliopathies: Lessons from interpreting genomic sequencing data and the requirement for accurate phenotypic data. <i>Annals of Human Genetics</i> , 2024, 88, 76-85.	0.8	0
366	Autosomal Dominant Polycystic Kidney Disease in Children and Adolescents: Assessing and Managing Risk of Progression. , 2023, 30, 236-244.		1
367	The natural history of autosomal dominant polycystic kidney disease. A strategy for grouping families and mutations. <i>Nefrologia</i> , 2023, 43, 120-125.	0.4	0
368	A novel heterozygous <scp><i>PKD1</i></scp> variant causing alternative splicing in a Chinese family with autosomal dominant polycystic kidney disease. <i>Molecular Genetics & Genomic Medicine</i> , 0, , .	1.2	0
369	Modifiers of Autosomal Dominant Polycystic Kidney Disease Severity: The Role of PKD1 Hypomorphic Alleles. <i>Genes</i> , 2023, 14, 1230.	2.4	1
370	è¥ā1'āšè...Žæ©Ÿèf1/2ā1/2Žā,ā,'èªā,āŸ <i>TSC2</i>éªā1/4ēēšā,āš <i>PKD1</i>i1/4CE <i>PKD2</i>éªā1/4ēēšā. <i>Nephrology</i> , 2023, 36, 61-66.	0.0	0
371	Predicting the Risk of Progression in Indian ADPKD Cohort using PROPKD Score â€“ A Single-Center Retrospective Study. <i>Indian Journal of Nephrology</i> , 2023, 33, 195-201.	0.5	0
372	Molecular Diagnosis and Identification of Novel Pathogenic Variants in a Large Cohort of Italian Patients Affected by Polycystic Kidney Diseases. <i>Genes</i> , 2023, 14, 1236.	2.4	0
374	An update on treatments for autosomal dominant polycystic kidney disease. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2023, 36, 11-16.	0.3	2

#	ARTICLE	IF	CITATIONS
375	Genomics in the kidney clinic. <i>Clinical Medicine</i> , 2023, 23, 246-249.	1.9	1
376	PKD1 Nonsense Variant in a Lagotto Romagnolo Family with Polycystic Kidney Disease. <i>Genes</i> , 2023, 14, 1210.	2.4	1
377	PKD1 Mutation Is a Biomarker for Autosomal Dominant Polycystic Kidney Disease. <i>Biomolecules</i> , 2023, 13, 1020.	4.0	1
378	Clinical Quality Control of MRI Total Kidney Volume Measurements in Autosomal Dominant Polycystic Kidney Disease. <i>Tomography</i> , 2023, 9, 1341-1355.	1.8	5
379	Mutation Analysis of <i>PKD1</i> and <i>PKD2</i> Genes in a Large Italian Cohort Reveals Novel Pathogenic Variants Including a Novel Complex Rearrangement. <i>Nephron</i> , 0, , 1-19.	1.8	1
380	Case report: Genotype-phenotype characteristics of nine novel PKD1 mutations in eight Chinese patients with autosomal dominant polycystic kidney disease. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
381	Development and Validation of a Nomogram for Renal Survival Prediction in Patients with Autosomal Dominant Polycystic Kidney Disease. <i>Kidney Diseases (Basel, Switzerland)</i> , 2023, 9, 398-407.	2.5	0
382	Cleavage fragments of the C-terminal tail of polycystin-1 are regulated by oxidative stress and induce mitochondrial dysfunction. <i>Journal of Biological Chemistry</i> , 2023, 299, 105158.	3.4	3
383	Baseline characteristics of the Korean genetic cohort of inherited cystic kidney disease. <i>Kidney Research and Clinical Practice</i> , 2023, 42, 617-627.	2.2	0
384	Genetic testing in the evaluation of recipient candidates and living kidney donors. <i>Current Opinion in Nephrology and Hypertension</i> , 0, , .	2.0	0
385	Exploring the clinical and genetical spectrum of ADPKD in Chile to assess ProPKD score as a risk prediction tool. <i>Translational Medicine Communications</i> , 2023, 8, .	1.4	0
386	Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study. <i>BMC Nephrology</i> , 2023, 24, .	1.8	1
387	Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers. <i>Frontiers in Pediatrics</i> , 0, 11, .	1.9	1
389	An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKD. <i>Kidney International Reports</i> , 2024, 9, 249-256.	0.8	0
390	Cystic Kidney Diseases in Children and Adults: Differences and Gaps in Clinical Management. <i>Seminars in Nephrology</i> , 2023, 43, 151434.	1.6	0
392	Dialysis and Transplant Considerations in Autosomal Dominant Polycystic Kidney Disease. , 2023, 30, 461-467.		1
393	Genetic Spectrum of Polycystic Kidney and Liver Diseases and the Resulting Phenotypes. , 2023, 30, 397-406.		1
394	Familial Variability of Disease Severity in Adult Patients With ADPKD. <i>Kidney International Reports</i> , 2024, 9, 649-660.	0.8	0

#	ARTICLE	IF	CITATIONS
395	Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan. Pediatric Nephrology, 0, , .	1.7	0
396	Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort. Scientific Reports, 2023, 13, .	3.3	0
398	Describing and Explaining ADPKD Variability Within Families. Kidney International Reports, 2024, 9, 523-525.	0.8	0
399	How Does ADPKD Severity Differ Between Family Members?. Kidney International Reports, 2024, 9, 1198-1209.	0.8	0
400	Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement. International Journal of Molecular Sciences, 2024, 25, 2554.	4.1	0
401	Comprehensive Analysis of <i>PKD1</i> and <i>PKD2</i> by Long-Read Sequencing in Autosomal Dominant Polycystic Kidney Disease. Clinical Chemistry, 0, , .	3.2	0
402	The screening, diagnosis, and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan. Nephrology, 2024, 29, 245-258.	1.6	0
403	Clinical Utility of Genetic Testing with Geographical Locations in ADPKD: Describing New Variants. Journal of Clinical Medicine, 2024, 13, 1751.	2.4	0